Should patients on isoniazid-based anti‑tuberculosis therapy receive pyridoxine (vitamin B6) supplementation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vitamin B for patients on anti‑TB meds

• Recommendation: Give pyridoxine (vitamin B6) 25–50 mg daily with isoniazid to all patients at increased neuropathy risk; if neuropathy develops, increase to 100 mg daily. 1, 2, 1

  • Who must receive B6 (give 25–50 mg/day from day 1):

    • Pregnant or breastfeeding (and breastfed infants of mothers on INH) 1, 2, 3
    • HIV infection, diabetes, alcoholism, malnutrition, chronic kidney disease, advanced age 1, 2, 1
    • Debilitated or poor nutritional intake; children with dietary risk or paresthesias 3
  • Dose adjustments:

    • Established peripheral neuropathy: pyridoxine 100 mg/day with INH until symptoms resolve, then 25–50 mg/day 1, 2, 1
    • Breastfed infants of mothers on INH: give infant pyridoxine supplementation (typical pediatric practice: 1–2 mg/kg/day up to ~25 mg/day) 3
  • Rationale tied to morbidity, mortality, QoL:

    • Prevents INH‑associated peripheral neuropathy, seizures, and neurotoxicity, which impair function and adherence, risking treatment failure and death. Multiple ATS/CDC/IDSA guidelines consistently endorse prophylaxis in at‑risk groups; the 2025 update strengthens to all patients on INH receiving 25–50 mg/day, aligning with safety and prevention priorities [4; corroborated by 1,2].
    • Biologic evidence shows INH lowers active B6 (PLP) levels rapidly; supplementation prevents deficiency and neuropathy 5.
  • Practical algorithm:

    1. If any risk factor present (see list above) or per 2025 ATS/CDC/ERS/IDSA update: start pyridoxine 25–50 mg/day with INH the same day therapy begins [4; 1,2].
    2. Monitor for paresthesias, burning feet, weakness; if present, increase to 100 mg/day and assess for other causes; continue INH if tolerated 1, 2.
    3. In pregnancy/breastfeeding: ensure mother 25–50 mg/day; give infant pyridoxine supplement while breastfeeding if mother on INH 1, 3.
    4. Continue B6 for the entire duration of INH therapy; stop when INH stops.
  • Pitfalls/caveats:

    • Do not rely on multivitamins alone—often <25 mg B6; prescribe dedicated pyridoxine 6.
    • Very high chronic B6 (>200 mg/day) may cause sensory neuropathy; stay within guideline doses (25–50 mg/day; 100 mg/day if symptomatic) [general safety; guideline dosing 1,2].
    • Children: routine prophylaxis is not universally mandated in all children, but give to breastfeeding infants and those with dietary risk or symptoms; many clinicians extend prophylaxis to high‑risk pediatric patients given safety and prevention benefits 3. The 2025 guideline table supports 25–50 mg/day with INH broadly, which can be applied with pediatric dosing considerations 4.
  • Scope:

    • This applies to any regimen that includes isoniazid (e.g., HRZE/HR). Not required for rifampin‑only regimens unless other indications. 1, 2

References

Research

The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.